Integrated local and global Ki67 profiling for prognostic stratification and therapeutic guidance in high-grade neuroendocrine neoplasms: a multicenter validation study

作者：Jin Chu, Haiyu Gong, Heli Gao, Zhigang Zhu, Juanhong Shi, Yihui Ma, Yuan Ji, Qiongyan Zhang, Lijuan Cao, Feng Tang, Yun Liang, Jie Chen, Weiqi Sheng, Qing-Chao Chen, Xiahai Zhuang, Dan Huang · 发表于：International Journal of Surgery · 年份：2025 · DOI：10.1097/js9.0000000000004574 · 研究领域：Neuroendocrine Tumor Research Advances、Thyroid Cancer Diagnosis and Treatment、Lung Cancer Research Studies

BACKGROUND: The distinction between high-grade neuroendocrine G3 tumors (G3 NETs) and carcinomas (NECs) is a critical diagnostic dilemma with profound therapeutic implications. Conventional Ki67 hotspot analysis often fails to provide robust risk stratification. We aimed to develop and validate a robust, interpretable digital pathology biomarker that overcomes these limitations to improve risk stratification and guide therapeutic decisions. METHODS: We developed the Integrated Local-Global Ki67 (IL-GKi67) score, which synergizes localized hotspot quantification with global intratumoral heterogeneity assessment from Ki67-stained whole-slide images. The score's prognostic and predictive performance was rigorously evaluated in a multicenter cohort (N = 349) with internal and external validation sets. RESULTS: The IL-GKi67 score was a powerful and independent prognostic factor, where high scores correlated with drastically worse overall survival (multicenter validation: HR = 4.169, P = 0.009), remaining significant where the traditional hotspot method failed (P = 0.128). Most importantly, IL-GKi67 functioned as a definitive predictive biomarker. Patients with low IL-GKi67 scores derived a profound survival benefit from adjuvant chemotherapy (mOS: 45.0 months, at 50 months, the restricted mean survival time of chemo subset was 48.9 months (95% CI, 45.36 to 52.02); HR = 0.069, P = 0.002), an effect particularly pronounced in the aggressive NEC subgroup (HR = 0.061, P < 0.001). The ...